Neuropharmacology

Contentshow allhide all

1. 2021

   • 185: 108449 - Effects of the NKCC1 inhibitors bumetanide, azosemide, and torasemide alone or in combination with phenobarbital on seizure threshold in epileptic and nonepileptic mice

     Hampel, Philip; Römermann, Kerstin; Gailus, Björn; Johne, Marie; Gericke, Birthe; Kaczmarek, Edith; Löscher, Wolfgang
2. 2020

   • 162: 107814 - The novel MAGL inhibitor MJN110 enhances responding to reward-predictive incentive cues by activation of CB1 receptors

     Feja, Malte; Leigh, Martin P. K.; Baindur, Ajay N.; McGraw, Justin J.; Wakabayashi, Ken T.; Cravatt, Benjamin F.; Bass, Caroline E.

   • 167: 107605 - The holy grail of epilepsy prevention: Preclinical approaches to antiepileptogenic treatments

     Löscher, Wolfgang

   • 170: 108055 - The feast and famine: Epilepsy treatment and treatment gaps in early 21st century

     Löscher, Wolfgang; Klein, Pavel

   • 162: 107817 - Selective inhibition of mTORC1/2 or PI3K/mTORC1/2 signaling does not prevent or modify epilepsy in the intrahippocampal kainate mouse model

     Gericke, Birthe; Brandt, Claudia; Theilmann, Wiebke; Welzel, Lisa; Schidlitzki, Alina; Twele, Friederike; Kaczmarek, Edith; Anjum, Syed Muhammad Muneeb; Hillmann, Petra; Löscher, Wolfgang

   • 180: 108297 - Novel brain permeant mTORC1/2 inhibitors are as efficacious as rapamycin or everolimus in mouse models of acquired partial epilepsy and tuberous sclerosis complex

     Theilmann, Wiebke; Gericke, Birthe; Schidlitzki, Alina; Muneeb Anjum, Syed Muhammad; Borsdorf, Saskia; Harries, Timon; Roberds, Steven L; Aguiar, Dean J; Brunner, Daniela; Leiser, Steven C; Song, Dekun; Fabbro, Doriano; Hillmann, Petra; Wymann, Matthias P; Löscher, Wolfgang